{"id":7656,"date":"2025-01-29T12:41:07","date_gmt":"2025-01-29T17:41:07","guid":{"rendered":"https:\/\/seci.wpenginepowered.com\/?p=7656"},"modified":"2025-01-29T12:41:12","modified_gmt":"2025-01-29T17:41:12","slug":"another-channel-stuffing-disclosure-enforcement","status":"publish","type":"post","link":"https:\/\/seciblog.pli.edu\/index.php\/another-channel-stuffing-disclosure-enforcement\/","title":{"rendered":"Another Channel Stuffing Disclosure Enforcement"},"content":{"rendered":"

On November 12, 2024, the SEC announced<\/a> yet another enforcement action focused on using sales incentives and similar strategies to achieve revenue targets without appropriate disclosure to investors about the use and impact of such strategies.\u00a0 This action focuses on Elanco Animal Health Inc. (Elanco), which was spun off by Eli Lilly and Company in 2018. (You can read about earlier cases in this blog post<\/a>.)<\/p>\n

As is typical of this kind of case, it began with a surprise stock drop.\u00a0 According to the SEC\u2019s\u00a0 Order<\/a>:<\/p>\n

\u201cOn May 7, 2020, Elaco announced an expected $160 million decline in revenue for the first and second quarters of 2020 that caused its share price to drop by over 13%. The statement cited the uncertainty of the COVID-19 pandemic and a \u2018strategic change\u2019 in Elanco\u2019s inventory management practices \u2013 including reductions in channel inventory \u2013 as the reason for the decline. Elanco publicly stated that it had not anticipated a strategic change to reduce channel inventory levels when it started the year.\u201d<\/p>\n

What the company did not disclose was that from the first quarter of 2019 to the first quarter of 2020 it had relied on incentives to generate sales to distributors to meet revenue targets. \u00a0Internally Elanco referred to these sales as the \u201cQuarter-End Incentivized Sales\u201d or \u201cIncentivized Sales.\u201d\u00a0 \u00a0Achieving revenue targets was particularly important for Elanco as a newly public company.\u00a0 As is usually the case, this practice could not go on indefinitely because inventory channels had become overstocked.<\/p>\n

When management knows there is a potential problem on the horizon (e.g., failing to meet sales growth expectations, as in this case), the known-trend MD&A requirements of S-K Item 303 require that companies disclose:<\/p>\n

\u201cKnown trends or uncertainties that have had or that the registrant reasonably expects will have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations.\u201d<\/p>\n

Again, from the SEC\u2019s Order:<\/p>\n

\u201cFrom May 2019 through May 2020, Elanco\u2019s public disclosures misled investors by attributing its revenue and revenue growth to strong consumer demand for its products while failing to disclose the material impact of its Quarter-End Incentivized Sales and the reasonably likely risk that such sales practices could have a negative impact on revenue in future quarters.<\/p>\n

Elanco\u2019s use of Quarter-End Incentivized Sales created an uncertainty or event that was known to Elanco\u2019s senior management and reasonably expected to have a material effect on its future revenues.\u201d<\/p>\n

The SEC also included the failure of Elanco\u2019s disclosure controls and procedures in the enforcement.<\/p>\n

One important aspect of this case relates to revenue recognition accounting.\u00a0 There was no issue with how and when Elanco recognized revenue.\u00a0 No accounting issues were raised in the AAER.\u00a0 This enforcement is all about disclosure.<\/p>\n

Elanco entered into a Cease-and-Desist Order and paid a $15,000,000 civil money penalty.<\/p>\n

As always, your thoughts and comments are welcome!<\/p>\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

On November 12, 2024, the SEC announced yet another enforcement action focused on using sales incentives and similar strategies to achieve revenue targets without appropriate disclosure to investors about the use and impact of such strategies.\u00a0 This action focuses on Elanco Animal Health Inc. (Elanco), which was spun off by Eli Lilly and Company in … Continue reading Another Channel Stuffing Disclosure Enforcement<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false},"categories":[261,143],"tags":[],"coauthors":[154],"class_list":["post-7656","post","type-post","status-publish","format-standard","hentry","category-enforcement","category-hot-topic"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/posts\/7656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/comments?post=7656"}],"version-history":[{"count":0,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/posts\/7656\/revisions"}],"wp:attachment":[{"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/media?parent=7656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/categories?post=7656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/tags?post=7656"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/seciblog.pli.edu\/index.php\/wp-json\/wp\/v2\/coauthors?post=7656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}